Cost-effectiveness of Talazoparib for Advanced Breast Cancer
Key Findings:
Talazoparib, a targeted PARP inhibitor, has shown significant extension in progression-free survival and improved response markers for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer, compared to conventional therapies.
Practical Solutions:
Our analysis aims to assess the cost-effectiveness of talazoparib in treating advanced breast cancer with germline BRCA1/2 mutations and HER2 negativity. The results provide valuable insights for rational drug utilization and enhancing medical resource efficiency.
Value:
Our study developed a Markov model based on the EMBRACA clinical trial to simulate the survival events of breast cancer patients in the Talazoparib group and the standard treatment group. The results indicate that Talazoparib is a cost-effective treatment strategy in both China and the United States, with superior clinical treatment effect and prolonged progression-free survival period.
AI-Driven Platform for Clinical Support:
DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.
Streamlining Healthcare Operations:
Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally, enhancing workflows and improving patient outcomes.
By using AI, clinics can reduce paper routines and enhance their workflows. Learn more about how we can help at aidevmd.com.
